Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 14/20 | 0.56 |
| ▸ | NPY1R | P25929 | 9/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.56 |
| ▸ | NPY2R | P49146 | 5/20 | 0.56 |
| ▸ | FNTA | P49354 | 3/20 | 0.52 |
| ▸ | FNTB | P49356 | 3/20 | 0.52 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1727150 | 1.00 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2RFNTA | |
| SCHEMBL1940080 | 1.00 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2RFNTA | |
| Acetic Acid SCHEMBL230815 | 0.98 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2RFNTA | |
| Acetic Acid SCHEMBL230814 | 0.98 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2RFNTA | |
| Acetic Acid SCHEMBL8587360 | 0.98 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2RFNTA | |
| Acetic Acid SCHEMBL2341088 | 0.97 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RFNTA | |
| Acetic Acid SCHEMBL2341079 | 0.97 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RFNTA | |
| SCHEMBL30866932 | 0.95 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2RFNTA | |
| SCHEMBL29619346 | 0.93 | FNTA (0.60) | NPY4RNPY1RNPY5RNPY2RFNTA | |
| SCHEMBL29352845 | 0.93 | FNTA (0.58) | NPY4RNPY1RNPY5RNPY2RFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11581179-B2 | Ion funnels and systems incorporating ion funnels | THERMO FINNIGAN LLC (US) | 2023-02-14 | — | — | US | claimed |
| US-20250313546-A1 | NUCLEIC ACID BINDERS | UNIVERSITY OF STRATHCLYDE (GB) | 2025-10-09 | — | — | US | disclosed |
| US-12362163-B2 | Molecular cryptographic sampling devices and methods of making and using | RESTEK CORPORATION (US) | 2025-07-15 | — | — | US | disclosed |
| EP-4522588-A1 | NUCLEIC ACID BINDERS | University of Strathclyde (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119585239-A | Nucleic acid binding agents | 斯特拉斯克莱德大学 | 2025-03-07 | — | — | CN | disclosed |
| US-11810773-B2 | Apparatus and methods for injecting ions into an electrostatic trap | THERMO FINNIGAN LLC (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230178356-A1 | APPARATUS AND METHODS FOR INJECTING IONS INTO AN ELECTROSTATIC TRAP | THERMO FINNIGAN LLC (US) | 2023-06-08 | — | — | US | disclosed |
| US-11581179-B2 | Ion funnels and systems incorporating ion funnels | THERMO FINNIGAN LLC (US) | 2023-02-14 | — | — | US | disclosed |
| US-11581180-B2 | Apparatus and methods for injecting ions into an electrostatic trap | THERMO FINNIGAN LLC (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220415641-A1 | APPARATUS AND METHODS FOR INJECTING IONS INTO AN ELECTROSTATIC TRAP | THERMO FINNIGAN LLC (US) | 2022-12-29 | — | — | US | disclosed |
| CN-217035584-U | Ion transmission apparatus | 萨默费尼根有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-217035585-U | Atmospheric to vacuum ion transport system | 萨默费尼根有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-114533753-A | Selenium-containing composition and application thereof in treating and preventing diseases or symptoms related to mitochondrial dysfunction | 全技术公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3999859-A1 | MOLECULAR CRYPTOGRAPHIC SAMPLING DEVICES AND METHODS OF MAKING AND USING | Restek Corporation (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20120148576-A1 | HUMANIZED ANTI-CD 19 ANTIBODY FORMULATIONS | MEDLMMUNE, LLC (US) | 2012-06-14 | — | — | US | disclosed |
| EP-2403532-A2 | HUMANIZED ANTI-CD19 ANTIBODY FORMULATIONS | MedImmune, LLC (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-1235852-B1 | METHOD FOR SEPARATING POLYNUCLEOTIDES USING MONOLITHIC CAPILLARY COLUMNS | TRANSGENOMIC INC (US) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010102276-A2 | HUMANIZED ANTI-CD19 ANTIBODY FORMULATIONS | MEDIMMUNE, LLC (US) | 2010-09-10 | — | — | WO | disclosed |
| US-7169298-B2 | Method and apparatus for separating polynucleotides using monolithic capillary columns | TRANSGENOMIC, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20020088753-A1 | Method and apparatus for separating polynucleotides using monolithic capillary columns | THIRD SECURITY SENIOR STAFF 2008 LLC | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313546-A1 | NUCLEIC ACID BINDERS | ZFR, NSUN3, POLI | NPY4R 4776/4885NPY1R 4778/4885NPY5R 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.